CytomX Therapeutics (CTMX) Long-Term Investments (2016 - 2021)

CytomX Therapeutics (CTMX) posted Long-Term Investments of $100.0 million for Q3 2021, little changed on a QoQ basis from $99.9 million in Q2 2021.

CytomX Therapeutics (CTMX) Long-Term Investments (2016 - 2021) Analysis & Trends

CytomX Therapeutics' Long-Term Investments history runs 2 years deep, the most recent figure standing at $100.0 million for Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	505,194.89
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	5.75 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	9.79 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	CytomX Therapeutics	574.36 Mn	227.66 Mn	-	-

Download Data